Search

Displaying results 3511 - 3520 of 6198 in total
  1. Drug

    Benactyzine

    go.drugbank.com/drugs/DB09023
    ApprovedWithdrawn

    Benactyzine is an anticholinergic drug used as an antidepressant in the treatment of depression and associated anxiety.

  2. Drug

    Lasalocid

    go.drugbank.com/drugs/DB11423
    ExperimentalVet approved

    Lasalocid is an agent that presents antibacterial and coccidiostat activities. It is produced by strains of _Streptomyces lasaliensis_.

  3. Drug

    Padeliporfin

    go.drugbank.com/drugs/DB15575
    ApprovedInvestigational

    [A244699] Padeliporfin was first approved by the European Commission on November 10, 2017, for the treatment of low-risk prostate cancer in adults meeting certain clinical criteria.[L39799]

  4. Drug

    Belladonna

    go.drugbank.com/drugs/DB13913
    Approved

    [DB00572] is a non-selective muscarinic antagonist that is mainly used as an adjunct for anaesthesia. … The name "belladonna" originates from the Italian words "beautiful woman" and the historical use of herb eye-drops by women to dilate the pupils of the eyes for aesthetic purposes.

  5. Drug

    HSV-2 theracine

    go.drugbank.com/drugs/DB05811
    Experimental

    HSV-2 theracine is an attenuated recombinant vaccine developed by AuRx for the treatment of genital herpes.

  6. Drug

    RTN-001

    go.drugbank.com/drugs/DB05615
    Investigational

    SLx-2101 is an oral, long-acting PDE5 inhibitor developed by Surface Logix Inc. to treat Hypertension.

  7. Drug

    Xylazine

    go.drugbank.com/drugs/DB11477
    InvestigationalVet approved

    [A9096] The use of xylazine can lead to hypotension and bradycardia[A9092,A9093], and when combined with central nervous system depressants, such as benzodiazepines or alcohol, it can significantly depress … Xylazine is a clonidine analog used as a non-opioid tranquilizer in veterinary medicine and as an emetic, especially in cats.

  8. Drug

    DG041

    go.drugbank.com/drugs/DB05027
    Experimental

    It block the formation of blood clots mediated through inflammation in atherosclerotic plaques but without increasing bleeding risk. … DG041, an anti-platelet compound, has shown to be a selective and potent antagonist of the EP3 receptor for prostaglandins E2.

  9. Drug

    Temanogrel

    go.drugbank.com/drugs/DB05227
    Investigational

    APD791 is an oral anti-thrombotic drug candidate being evaluated in a Phase 1 clinical trial by Arena. … APD791 is intended to lower the risk of arterial thrombosis by reducing the amplification of platelet aggregation, arterial constriction and intimal hyperplasia mediated by serotonin.

  10. Drug

    Laropiprant

    go.drugbank.com/drugs/DB11629
    ApprovedWithdrawn

    Laropiprant is an ingredient in the EMA-withdrawn product Pelzont.